Adam Feuerstein
- Article Tools
- Email this Article
- Print this Article
- Rss Feed
- Related Articles
- Del.icio.us
- Digg
- StumbleUpon
Forest LaboratoriesFRX said its fiscal third-quarter profits doubled on strong sales of its antidepressant drugs. The New York-based drugmaker also forecast better-than-expected results for its fiscal fourth quarter, which ends March 31. Forest said net income during the quarter roughly doubled to $174.6 million, or 47 cents a share, adjusted for a 2-for-1 stock split on Dec. 23. Analysts were expecting earnings of 45 cents a share, according to the consensus estimate compiled by Thomson Financial/First Call. Sales in the quarter rose 46% to $586.8 million. Forest's antidepressant franchise -- Celexa and Lexapro -- contributed $452.2 million in sales during the quarter. Looking ahead, Forest says it expects earnings for its fiscal fourth quarter to be comparable with this quarter's results. Wall Street is currently expecting earnings of 45 cents per share.
Yahoo! is among the most searched stocks on TheStreet.com. Here's what Cramer had to say about the stock recently.
Catch up on his thinking on the hottest topics of the past week.
Investors will have to deal with a Fed meeting and another flood of earnings and economic data.
Ensco International and Echelon have the potential to move higher in coming days.
See who made what calls.
The addition of video is helping telecom companies compete against cable and satellite companies.
The June West Texas Intermediate contract reflects selling pressure ahead of Tuesday's expiration. But stocks in the sector are generally trading higher.
See who made what calls.
Keep on top of the market and the critical information you need to make more profitable investing decisions.
Sponsored by:
RSS
